Curasight receives EPO patent notification with issue date 28 August 2019 and patent number 2928505

Curasight have provided a positron-emitting radionuclide labelled peptide (uTRACE®) for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans.

Curasight has developed a novel radiopharmaceutical platform (uTRACE®) for improved diagnose, risk stratification and treatment monitoring for cancer patients based on uPAR PET Imaging within different cancer indications.

More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

The validation of this European patent has now been officially confirmed by the European Patent Office, and this is a major milestone for the further development of uTRACE® and of major strategic importance for Curasight’s strategy into the European market.